Off-label use of dexmedetomidine in paediatric anaesthesiology: an international survey of 791 (paediatric) anaesthesiologists

Camille E van Hoorn, Robert B Flint, Justin Skowno, Paul Davies, Thomas Engelhardt, Kirk Lalwani, Olutoyin Olutoye, Erwin Ista, Jurgen C de Graaff, Camille E van Hoorn, Robert B Flint, Justin Skowno, Paul Davies, Thomas Engelhardt, Kirk Lalwani, Olutoyin Olutoye, Erwin Ista, Jurgen C de Graaff

Abstract

Purpose: The purpose of this international study was to investigate prescribing practices of dexmedetomidine by paediatric anaesthesiologists.

Methods: We performed an online survey on the prescription rate of dexmedetomidine, route of administration and dosage, adverse drug reactions, education on the drug and overall experience. Members of specialist paediatric anaesthesia societies of Europe (ESPA), New Zealand and Australia (SPANZA), Great Britain and Ireland (APAGBI) and the USA (SPA) were consulted. Responses were collected in July and August 2019.

Results: Data from 791 responders (17% of 5171 invitees) were included in the analyses. Dexmedetomidine was prescribed by 70% of the respondents (ESPA 53%; SPANZA 69%; APAGBI 34% and SPA 96%), mostly for procedural sedation (68%), premedication (46%) and/or ICU sedation (46%). Seventy-three percent had access to local or national protocols, although lack of education was the main reason cited by 26% of the respondents not to prescribe dexmedetomidine. The main difference in dexmedetomidine use concerned the age of patients (SPA primarily < 1 year, others primarily > 1 year). The dosage varied widely ranging from 0.2-5 μg kg-1 for nasal premedication, 0.2-8 μg kg-1 for nasal procedural sedation and 0-4 μg kg-1 intravenously as adjuvant for anaesthesia. Only ESPA members (61%) had noted an adverse drug reaction, namely bradycardia.

Conclusion: The majority of anaesthesiologists use dexmedetomidine in paediatrics for premedication, procedural sedation, ICU sedation and anaesthesia, despite the off-label use and sparse evidence. The large intercontinental differences in prescribing dexmedetomidine call for consensus and worldwide education on the optimal use in paediatric practice.

Keywords: Anaesthesia; Dexmedetomidine; Drug prescriptions; Off-label use; Paediatrics; Pharmacology.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Distribution and response diagram of the survey
Fig. 2
Fig. 2
Reasons why respondents started using dexmedetomidine. Multiple answers possible
Fig. 3
Fig. 3
Reasons why respondents do not use dexmedetomidine. Multiple answers possible

References

    1. Afonso J, Reis F. Dexmedetomidine: current role in anesthesia and intensive care. Rev Bras Anestesiol. 2012;62(1):118–133. doi: 10.1016/s0034-7094(12)70110-1.
    1. Sulton C, McCracken C, Simon HK, Hebbar K, Reynolds J, Cravero J, Mallory M, Kamat P. Pediatric procedural sedation using dexmedetomidine: a report from the Pediatric Sedation Research Consortium. Hosp Pediatr. 2016;6(9):536–544. doi: 10.1542/hpeds.2015-0280.
    1. Bellon M, Le Bot A, Michelet D, Hilly J, Maesani M, Brasher C, Dahmani S. Efficacy of intraoperative dexmedetomidine compared with placebo for postoperative pain management: a meta-analysis of published studies. Pain Ther. 2016;5(1):63–80. doi: 10.1007/s40122-016-0045-2.
    1. Szmuk P, Andropoulos D, McGowan F, Brambrink A, Lee C, Lee KJ, McCann ME, Liu Y, Saynhalath R, Bong CL, Anderson BJ, Berde C, De Graaff JC, Disma N, Kurth D, Loepke A, Orser B, Sessler DI, Skowno JJ, von Ungern-Sternberg BS, Vutskits L, Davidson A. An open label pilot study of a dexmedetomidine-remifentanil-caudal anesthetic for infant lower abdominal/lower extremity surgery: the T REX pilot study. Paediatr Anaesth. 2019;29(1):59–67. doi: 10.1111/pan.13544.
    1. Gupta A, Dalvi NP, Tendolkar BA. Comparison between intranasal dexmedetomidine and intranasal midazolam as premedication for brain magnetic resonance imaging in pediatric patients: a prospective randomized double blind trial. J Anaesthesiol Clin Pharmacol. 2017;33(2):236–240. doi: 10.4103/joacp.JOACP_204_16.
    1. Yuen VM, Irwin MG, Hui TW, Yuen MK, Lee LH. A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine. Anesth Analg. 2007;105(2):374–380. doi: 10.1213/01.ane.0000269488.06546.7c.
    1. Weatherall M, Aantaa R, Conti G, Garratt C, Pohjanjousi P, Lewis MA, Moore N, Perez-Gutthann S. A multinational, drug utilization study to investigate the use of dexmedetomidine (Dexdor®) in clinical practice in the EU. Br J Clin Pharmacol. 2017;83(9):2066–2076. doi: 10.1111/bcp.13293.
    1. FDA (2016) PRECEDEX safety and drug utilisation review. FDA
    1. van Hoorn CE, Hoeks SE, Essink H, Tibboel D, de Graaff JC. A systematic review and narrative synthesis on the histological and neurobehavioral long-term effects of dexmedetomidine. Paediatr Anaesth. 2019;29(2):125–136. doi: 10.1111/pan.13553.
    1. Sanders RD, Sun P, Patel S, Li M, Maze M, Ma D. Dexmedetomidine provides cortical neuroprotection: impact on anaesthetic-induced neuroapoptosis in the rat developing brain. Acta Anaesthesiol Scand. 2010;54(6):710–716. doi: 10.1111/j.1399-6576.2009.02177.x.
    1. (2019) A phase I study of dexmedetomidine bolus and infusion in corrective infant cardiac surgery: safety and pharmacokinetics. . Accessed September 16 2019
    1. Damian MA, Hammer GB, Elkomy MH, Frymoyer A, Drover DR, Su F. Pharmacokinetics of dexmedetomidine in infants and children after orthotopic liver transplantation. Anesth Analg. 2020;130(1):209–216. doi: 10.1213/ane.0000000000003761.
    1. Uusalo P, Guillaume S, Siren S, Manner T, Vilo S, Scheinin M, Saari TI. Pharmacokinetics and sedative effects of intranasal dexmedetomidine in ambulatory pediatric patients. Anesth Analg. 2019;130:949–957. doi: 10.1213/ane.0000000000004264.
    1. van Dijkman SC, De Cock P, Smets K, Decaluwe W, Smits A, Allegaert K, Vande Walle J, De Paepe P, Della Pasqua O. Dose rationale and pharmacokinetics of dexmedetomidine in mechanically ventilated new-borns: impact of design optimisation. Eur J Clin Pharmacol. 2019;75(10):1393–1404. doi: 10.1007/s00228-019-02708-y.
    1. Weerink MAS, Struys M, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–913. doi: 10.1007/s40262-017-0507-7.
    1. Zimmerman KO, Wu H, Laughon M, Greenberg RG, Walczak R, Schulman SR, Smith PB, Hornik CP, Cohen-Wolkowiez M, Watt KM. Dexmedetomidine pharmacokinetics and a new dosing paradigm in infants supported with cardiopulmonary bypass. Anesth Analg. 2019;129(6):1519–1528. doi: 10.1213/ane.0000000000003700.
    1. Tait AR, Voepel-Lewis T. Survey research: it’s just a few questions, right? Paediatr Anaesth. 2015;25(7):656–662. doi: 10.1111/pan.12680.
    1. Mahmoud M, Mason KP. Dexmedetomidine: review, update, and future considerations of paediatric perioperative and periprocedural applications and limitations. Br J Anaesth. 2015;115(2):171–182. doi: 10.1093/bja/aev226.
    1. FDA (2016) FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. Communications DS
    1. Hansen TG. Use of anesthetics in young children Consensus statement of the European Society of Anaesthesiology (ESA), the European Society for Paediatric Anaesthesiology (ESPA), the European Association of Cardiothoracic Anaesthesiology (EACTA), and the European Safe Tots Anaesthesia Research Initiative (EuroSTAR) Paediatr Anaesth. 2017;27(6):558–559. doi: 10.1111/pan.13160.
    1. Al-Zaben KR, Qudaisat IY, Al-Ghanem SM, Massad IM, Al-Mustafa MM, Al-Oweidi AS, Abu-Halaweh SA, Abu-Ali HM, Saleem MM. Intraoperative administration of dexmedetomidine reduces the analgesic requirements for children undergoing hypospadius surgery. Eur J Anaesthesiol. 2010;27(3):247–252. doi: 10.1097/EJA.0b013e32833522bf.
    1. Gurbet A, Basagan-Mogol E, Turker G, Ugun F, Kaya FN, Ozcan B. Intraoperative infusion of dexmedetomidine reduces perioperative analgesic requirements. Can J Anaesth. 2006;53(7):646–652. doi: 10.1007/bf03021622.
    1. Olutoye OA, Glover CD, Diefenderfer JW, McGilberry M, Wyatt MM, Larrier DR, Friedman EM, Watcha MF. The effect of intraoperative dexmedetomidine on postoperative analgesia and sedation in pediatric patients undergoing tonsillectomy and adenoidectomy. Anesth Analg. 2010;111(2):490–495. doi: 10.1213/ANE.0b013e3181e33429.
    1. Song J, Ji Q, Sun Q, Gao T, Liu K, Li L. The opioid-sparing effect of intraoperative dexmedetomidine infusion after craniotomy. J Neurosurg Anesthesiol. 2016;28(1):14–20. doi: 10.1097/ana.0000000000000190.
    1. Vilo S, Rautiainen P, Kaisti K, Aantaa R, Scheinin M, Manner T, Olkkola KT. Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. Br J Anaesth. 2008;100(5):697–700. doi: 10.1093/bja/aen070.
    1. McAdams RM, Pak D, Lalovic B, Phillips B, Shen DD. Dexmedetomidine pharmacokinetics in neonates with hypoxic-ischemic encephalopathy receiving hypothermia. Anesthesiol Res Pract. 2020;2020:2582965–2582915. doi: 10.1155/2020/2582965.
    1. Song IK, Yi S, Lim HS, Lee JH, Kim EH, Cho JY, Kim MC, Kim JT, Kim HS (2019) A population pharmacokinetic model of intravenous dexmedetomidine for mechanically ventilated children after neurosurgery. J Clin Med 8(10). 10.3390/jcm8101563
    1. Wang CY, Ihmsen H, Hu ZY, Chen J, Ye XF, Chen F, Lu Y, Schüttler J, Lian QQ, Liu HC. Pharmacokinetics of intranasally administered dexmedetomidine in Chinese children. Front Pharmacol. 2019;10:756. doi: 10.3389/fphar.2019.00756.
    1. Pérez-Guillé MG, Toledo-López A, Rivera-Espinosa L, Alemon-Medina R, Murata C, Lares-Asseff I, Chávez-Pacheco JL, Gómez-Garduño J, Zamora Gutiérrez AL, Orozco-Galicia C, Ramírez-Morales K, Lugo-Goytia G. Population pharmacokinetics and pharmacodynamics of dexmedetomidine in children undergoing ambulatory surgery. Anesth Analg. 2018;127(3):716–723. doi: 10.1213/ane.0000000000003413.
    1. Jin S, Liang DD, Chen C, Zhang M, Wang J. Dexmedetomidine prevent postoperative nausea and vomiting on patients during general anesthesia: a PRISMA-compliant meta analysis of randomized controlled trials. Medicine. 2017;96(1):e5770–e5770. doi: 10.1097/MD.0000000000005770.
    1. Yu YM, Shin WG, Lee JY, Choi SA, Jo YH, Youn SJ, Lee MS, Choi KH. Patterns of adverse drug reactions in different age groups: analysis of spontaneous reports by community pharmacists. PLoS One. 2015;10(7):e0132916. doi: 10.1371/journal.pone.0132916.
    1. Smith MC, Williamson J, Yaster M, Boyd GJC, Heitmiller ES. Off-label use of medications in children undergoing sedation and anesthesia. Anesth Analg. 2012;115(5):1148–1154. doi: 10.1213/ANE.0b013e3182501b04.
    1. Tobin JR. Use of pharmaceuticals ‘off-label’ in the neonate. Best Pract Res Clin Anaesthesiol. 2010;24(3):451–460. doi: 10.1016/j.bpa.2010.02.015.
    1. Pratico AD, Longo L, Mansueto S, Gozzo L, Barberi I, Tiralongo V, Salvo V, Falsaperla R, Vitaliti G, La Rosa M, Leonardi S, Rotondo A, Avola N, Sgarlata D, Damiano A, Tirantello M, Anzelmo G, Cipolla D, Rizzo A, Russo A, Ruggieri M, Salomone S, Drago F. Off-label use of drugs and adverse drug reactions in pediatric units: a prospective, multicenter study. Curr Drug Saf. 2018;13(3):200–207. doi: 10.2174/1574886313666180619120406.
    1. Gore R, Chugh PK, Tripathi CD, Lhamo Y, Gautam S. Pediatric off-label and unlicensed drug use and its implications. Curr Clin Pharmacol. 2017;12(1):18–25. doi: 10.2174/1574884712666170317161935.
    1. Goh AN, Bagshaw O, Courtman S. A follow-up survey of total intravenous anesthesia usage in children in the U.K. and Ireland. Paediatr Anaesth. 2019;29(2):180–185. doi: 10.1111/pan.13556.
    1. O’Brien MA, Rogers S, Jamtvedt G, Oxman AD, Odgaard-Jensen J, Kristoffersen DT, Forsetlund L, Bainbridge D, Freemantle N, Davis DA, Haynes RB, Harvey EL (2007) Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (4):Cd000409. 10.1002/14651858.CD000409.pub2
    1. Flodgren G, Parmelli E, Doumit G, Gattellari M, O’Brien MA, Grimshaw J, Eccles MP (2011) Local opinion leaders: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (8):Cd000125. 10.1002/14651858.CD000125.pub4
    1. Martin F, Bannard-Smith J, Blackburn T. Dexmedetomidine: a valuable sedative currently not widely available in the UK. Br J Anaesth. 2016;117(2):263–264. doi: 10.1093/bja/aew202.
    1. Agency EM (2011) Assessment Report: Dexdor. . Accessed March 27 2020
    1. Plambech MZ, Afshari A. Dexmedetomidine in the pediatric population: a review. Minerva Anestesiol. 2015;81(3):320–332.
    1. Flint RB, van Beek F, Andriessen P, Zimmermann LJ, Liem KD, IKM R, de Groot R, Tibboel D, Burger DM, SHP S, group DR Large differences in neonatal drug use between NICUs are common practice: time for consensus? Br J Clin Pharmacol. 2018;84(6):1313–1323. doi: 10.1111/bcp.13563.
    1. FDA (2020) FDA adverse event reporting system (FAERS). FDA. . Accessed August 13 2020
    1. Yang F, Liu Y, Yu Q, Li S, Zhang J, Sun M, Liu L, Lei Y, Tian Q, Liu H, Tu S. Analysis of 17 948 pediatric patients undergoing procedural sedation with a combination of intranasal dexmedetomidine and ketamine. Paediatr Anaesth. 2019;29(1):85–91. doi: 10.1111/pan.13526.
    1. Brasel K, Haider A, Haukoos J. Practical guide to survey research. JAMA Surg. 2020;155:351–352. doi: 10.1001/jamasurg.2019.4401.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe